Roswell Park Offering CAR T Trial for Autoimmune Conditions - Summary - MDSpire
Advertisement
Roswell Park Offering CAR T Trial for Autoimmune Conditions
While most CAR T-cell therapies and clinical trials are directed at cancers, a new phase 1 trial at Roswell Park Comprehensive Cancer Center is open and recruiting patients with a variety of autoimmune conditions.
To evaluate the efficacy of CD20-directed CAR T-cell therapy in patients with refractory autoimmune conditions.
Key Findings:
The trial aims to achieve a deep immune reset for better long-term control of autoimmune conditions.
The CAR T-cells used are gamma-delta T-cells, which target inflamed tissues and lymph nodes effectively.
Interpretation:
This trial represents a novel approach to treating autoimmune diseases, leveraging CAR T-cell technology typically used in cancer therapy.
Limitations:
Phase 1 trial may have a limited sample size and preliminary results.
The long-term effects and safety of this treatment in autoimmune conditions are yet to be established.
Conclusion:
The trial at Roswell Park is the only one in the U.S. utilizing this specific CAR T-cell therapy for autoimmune conditions, potentially paving the way for new treatment options.
